RealFeedApp Eli Lilly beats analyst forecasts by 8%
The company raised full-year guidance by $5 billion, addressing investor concerns about the Medicare Bridge program and GLP-1 pricing dynamics.
- Field
- drugs and trials
- What they did
- Eli Lilly reported third-quarter revenue 8% above analyst forecasts, raising full-year guidance by $5 billion due to strong sales of its diabetes and obesity drugs.
- Why it matters
- This result reassures investors who were concerned that Medicare's program might negatively impact revenue from weight-loss medications.
#eli lilly#mounjaro#zebound#glp-1#earnings
